UBS analyst AJ Rice raised the firm’s price target on Tenet Healthcare (THC) to $230 from $217 and keeps a Buy rating on the shares. Labor efficiencies drove a fundamental outperformance, and the runway remains high for the high-acuity ambulatory surgery center strategy, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $180 from $165 at Guggenheim
- Tenet Healthcare price target raised to $171 from $161 at Barclays
- Tenet Healthcare’s Strategic Expansion and Strong Financial Performance Highlighted by Conservative Guidance and Robust Margins
- Tenet Healthcare Reports Strong Q1 2025 Results
- Tenet Healthcare’s Strong Q1 Performance Amid Policy Uncertainty